Patents Assigned to Maxygen Aps
-
Patent number: 7431921Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: GrantFiled: June 27, 2003Date of Patent: October 7, 2008Assignee: Maxygen ApSInventors: Poul Baad Rasmussen, Grethe Rasmussen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7338788Abstract: The present invention provides new interferon ? conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: GrantFiled: January 24, 2003Date of Patent: March 4, 2008Assignee: Maxygen ApSInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Patent number: 7226999Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and ?1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.Type: GrantFiled: December 3, 2004Date of Patent: June 5, 2007Assignees: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Kim Vilbour Andersen, Anders Hjelholt Pedersen, Per Ola Freskgaard
-
Patent number: 7144574Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: GrantFiled: February 26, 2002Date of Patent: December 5, 2006Assignee: Maxygen ApSInventors: Poul Baad Rasmussen, Grethe Rasmussen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 6958388Abstract: When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated. Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells.Type: GrantFiled: July 15, 2002Date of Patent: October 25, 2005Assignee: Maxygen, ApSInventors: Bart Van Den Hazel, Anne Dam Jensen, Frank Bech. Nygaard, Kim Vilbour Andersen
-
Patent number: 6933367Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and ?1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.Type: GrantFiled: November 29, 2001Date of Patent: August 23, 2005Assignees: Maxygen Aps, Maxygen Holdings, Ltd.Inventors: Kim Vilbour Andersen, Anders Hjelholt Pedersen, Per Ola Freskgaard
-
Patent number: 6806063Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: February 12, 2001Date of Patent: October 19, 2004Assignees: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20040013644Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: June 27, 2003Publication date: January 22, 2004Applicants: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20040014948Abstract: The invention relates to a single-chain oilgomeric polypeptide antagonist which binds to an extracellular ligand-binding domain of a cellular receptor of a type requiring binding of an oligomeric ligand to two or more receptor subunits to be activated, the polypeptide comprising at least two, typically structurally homologous, receptor-binding sites of which at least one is capable of binding to a ligand-binding domain of the cellular receptor and at least one is incapable of effectively binding to a ligand-binding domain of the cellular receptor, whereby the single-chain oligomeric polypeptide is capable of binding to the receptor, but incapable of activating the receptor; as well as to nucleotide sequences encoding such single-chain oligomeric polypeptides, expression vectors comprising such a nucleotide sequence, recombinant host cells comprising such a nucleotide sequence or expression vector, methods for producing the nucleotide sequences and polypeptides, pharmaceutical compositions comprising the singlType: ApplicationFiled: May 23, 2003Publication date: January 22, 2004Applicant: Maxygen ApSInventors: Torben Halkier, Hans Thalsgard Schambye, Jens Sigurd Okkels, Kim Vilbour Andersen, Torben Lauesgaard Nissen, Bobby Soni, Claus Bekker Jeppesen, Bart van den Hazel
-
Publication number: 20040009165Abstract: A polypeptide selected from the group of lysosomal enzymes and lysosomal enzyme activators, comprising at least one introduced glycosylation site as compared to a corresponding parent enzyme or activator. By introducing additional glycosylation sites the resulting glycosylated lysosomal enzyme or activator obtains improved in vivo activity and thereby provides for improved treatment of lysosomal storage diseases.Type: ApplicationFiled: December 27, 2002Publication date: January 15, 2004Applicant: Maxygen ApSInventors: Jens Sigurd Okkels, Anne Dam Jensen, Torben Halkier, Rikke Bolding Jensen, Hans Thalsgard Schambye
-
Publication number: 20030175240Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: ApplicationFiled: December 19, 2002Publication date: September 18, 2003Applicant: Maxygen ApSInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Publication number: 20030176328Abstract: The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue.Type: ApplicationFiled: December 20, 2002Publication date: September 18, 2003Applicant: Maxygen ApSInventors: Poul Baad Rasmussen, Kim Vilbour Andersen, Anders Hjelholt Pedersen, Hans Thalsgaard Schambye, Torben Halkier, Are Bogsnes
-
Publication number: 20030175241Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: ApplicationFiled: January 24, 2003Publication date: September 18, 2003Applicant: Maxygen ApSInventors: Anders Hjelholt Pedersen, Hans Thalsgaard Schambye, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Publication number: 20030170206Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: February 26, 2002Publication date: September 11, 2003Applicant: Maxygen ApSInventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20030138403Abstract: The invention relates to interferon compositions, such as pharmaceutical interferon compositions and methods of their preparation. In particular it relates to stabilized compositions comprising an interferon molecule and a sulfoalkyl ether cyclodextrin derivative.Type: ApplicationFiled: June 28, 2002Publication date: July 24, 2003Applicant: Maxygen ApSInventor: Joern Drustrup
-
Patent number: 6531122Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: GrantFiled: August 25, 2000Date of Patent: March 11, 2003Assignee: MaxyGen ApSInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Paul Baad Rasmussen
-
Publication number: 20030018175Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and &agr;1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.Type: ApplicationFiled: November 29, 2001Publication date: January 23, 2003Applicant: Maxygen ApSInventors: Kim Vilbour Andersen, Anders Hjelholt Pedersen, Per Ola Freskgaard